RE: What is actually going on?17 Jul 2024 20:31
Great article Stu. thank you. there may be a few hurdles but seems little doubt about CAR T benefits
''Yescarta’s overall survival win now serves as a wake-up call for some CAR-T doubters, Biddle suggested. And Graybosch agreed that a life-extension benefit, a gold-standard measurement of efficacy, will fuel more referrals.
Toward the end of 2023, the FDA added the impressive overall survival data to Yescarta’s label. The regulatory move allows Kite to promote the information to doctors, although Biddle acknowledged that changing nearly three decades of practice will take time''